Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients

Basem Azab, Neeraj Shah, Jared Radbel, Pamela Tan, Vijaya Bhatt, Steven Vonfrolio, Ayman Habeshy, Antonio Picon, Scott Bloom

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

The aim of our study was to assess the predictive value of platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR) in terms of survival in breast cancer patients. This is an observational study of 437 breast cancer patients treated between January 2004 and December 2006. Survival status was obtained from our cancer registry and Social Security Death Index. Survival analysis, stratified by NLR and PLR quartiles, was used to evaluate their prognostic values. Patients in the highest 4th PLR and NLR quartiles had higher 5-year mortality rate (30.4 and 40.3 %) compared to those in the lower three PLR and NLR quartiles (12.1 and 8.2 %), p < 0.0001. Multivariate hazard ratios of 4th PLR and NLR quartiles compared to first PLR and NLR quartiles were 3.68 (1.74-7.77, p = 0.001) and 3.67 (1.52-8.86, p = 0.004). Higher PLR only showed a trend of higher mortality in patients with normal lymphocyte count, whereas NLR continued to be statistically significant predictor of 5-year mortality in all lymphocyte count subsets. Pretreatment NLR is an independent predictor of long-term mortality in breast cancer patients, whereas pretreatment PLR was not superior to absolute lymphocyte count alone in predicting long-term mortality.

Original languageEnglish (US)
Article number432
JournalMedical Oncology
Volume30
Issue number1
DOIs
StatePublished - Mar 1 2013

Fingerprint

Neutrophils
Blood Platelets
Lymphocytes
Breast Neoplasms
Mortality
Lymphocyte Count
Survival
Social Security
Lymphocyte Subsets
Survival Analysis
Observational Studies
Registries

Keywords

  • Breast cancer
  • Mortality
  • NLR
  • Neutrophil-lymphocyte ratio
  • PLR
  • Platelet-lymphocyte ratio

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. / Azab, Basem; Shah, Neeraj; Radbel, Jared; Tan, Pamela; Bhatt, Vijaya; Vonfrolio, Steven; Habeshy, Ayman; Picon, Antonio; Bloom, Scott.

In: Medical Oncology, Vol. 30, No. 1, 432, 01.03.2013.

Research output: Contribution to journalArticle

Azab, Basem ; Shah, Neeraj ; Radbel, Jared ; Tan, Pamela ; Bhatt, Vijaya ; Vonfrolio, Steven ; Habeshy, Ayman ; Picon, Antonio ; Bloom, Scott. / Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. In: Medical Oncology. 2013 ; Vol. 30, No. 1.
@article{09ddda8973b14a3285541b8fbdd9185c,
title = "Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients",
abstract = "The aim of our study was to assess the predictive value of platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR) in terms of survival in breast cancer patients. This is an observational study of 437 breast cancer patients treated between January 2004 and December 2006. Survival status was obtained from our cancer registry and Social Security Death Index. Survival analysis, stratified by NLR and PLR quartiles, was used to evaluate their prognostic values. Patients in the highest 4th PLR and NLR quartiles had higher 5-year mortality rate (30.4 and 40.3 {\%}) compared to those in the lower three PLR and NLR quartiles (12.1 and 8.2 {\%}), p < 0.0001. Multivariate hazard ratios of 4th PLR and NLR quartiles compared to first PLR and NLR quartiles were 3.68 (1.74-7.77, p = 0.001) and 3.67 (1.52-8.86, p = 0.004). Higher PLR only showed a trend of higher mortality in patients with normal lymphocyte count, whereas NLR continued to be statistically significant predictor of 5-year mortality in all lymphocyte count subsets. Pretreatment NLR is an independent predictor of long-term mortality in breast cancer patients, whereas pretreatment PLR was not superior to absolute lymphocyte count alone in predicting long-term mortality.",
keywords = "Breast cancer, Mortality, NLR, Neutrophil-lymphocyte ratio, PLR, Platelet-lymphocyte ratio",
author = "Basem Azab and Neeraj Shah and Jared Radbel and Pamela Tan and Vijaya Bhatt and Steven Vonfrolio and Ayman Habeshy and Antonio Picon and Scott Bloom",
year = "2013",
month = "3",
day = "1",
doi = "10.1007/s12032-012-0432-4",
language = "English (US)",
volume = "30",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "1357-0560",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients

AU - Azab, Basem

AU - Shah, Neeraj

AU - Radbel, Jared

AU - Tan, Pamela

AU - Bhatt, Vijaya

AU - Vonfrolio, Steven

AU - Habeshy, Ayman

AU - Picon, Antonio

AU - Bloom, Scott

PY - 2013/3/1

Y1 - 2013/3/1

N2 - The aim of our study was to assess the predictive value of platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR) in terms of survival in breast cancer patients. This is an observational study of 437 breast cancer patients treated between January 2004 and December 2006. Survival status was obtained from our cancer registry and Social Security Death Index. Survival analysis, stratified by NLR and PLR quartiles, was used to evaluate their prognostic values. Patients in the highest 4th PLR and NLR quartiles had higher 5-year mortality rate (30.4 and 40.3 %) compared to those in the lower three PLR and NLR quartiles (12.1 and 8.2 %), p < 0.0001. Multivariate hazard ratios of 4th PLR and NLR quartiles compared to first PLR and NLR quartiles were 3.68 (1.74-7.77, p = 0.001) and 3.67 (1.52-8.86, p = 0.004). Higher PLR only showed a trend of higher mortality in patients with normal lymphocyte count, whereas NLR continued to be statistically significant predictor of 5-year mortality in all lymphocyte count subsets. Pretreatment NLR is an independent predictor of long-term mortality in breast cancer patients, whereas pretreatment PLR was not superior to absolute lymphocyte count alone in predicting long-term mortality.

AB - The aim of our study was to assess the predictive value of platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR) in terms of survival in breast cancer patients. This is an observational study of 437 breast cancer patients treated between January 2004 and December 2006. Survival status was obtained from our cancer registry and Social Security Death Index. Survival analysis, stratified by NLR and PLR quartiles, was used to evaluate their prognostic values. Patients in the highest 4th PLR and NLR quartiles had higher 5-year mortality rate (30.4 and 40.3 %) compared to those in the lower three PLR and NLR quartiles (12.1 and 8.2 %), p < 0.0001. Multivariate hazard ratios of 4th PLR and NLR quartiles compared to first PLR and NLR quartiles were 3.68 (1.74-7.77, p = 0.001) and 3.67 (1.52-8.86, p = 0.004). Higher PLR only showed a trend of higher mortality in patients with normal lymphocyte count, whereas NLR continued to be statistically significant predictor of 5-year mortality in all lymphocyte count subsets. Pretreatment NLR is an independent predictor of long-term mortality in breast cancer patients, whereas pretreatment PLR was not superior to absolute lymphocyte count alone in predicting long-term mortality.

KW - Breast cancer

KW - Mortality

KW - NLR

KW - Neutrophil-lymphocyte ratio

KW - PLR

KW - Platelet-lymphocyte ratio

UR - http://www.scopus.com/inward/record.url?scp=84871690791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871690791&partnerID=8YFLogxK

U2 - 10.1007/s12032-012-0432-4

DO - 10.1007/s12032-012-0432-4

M3 - Article

C2 - 23283648

AN - SCOPUS:84871690791

VL - 30

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 1357-0560

IS - 1

M1 - 432

ER -